* Chromadex Corp reported quarterly adjusted earnings of 2 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -1 cents. The mean expectation of four analysts for the quarter was for breakeven results per share. Wall Street expected results to range from zero cents to 1 cents per share.
* Revenue rose 31.2% to $25.58 million from a year ago; analysts expected $23.64 million.
* Chromadex Corp's reported EPS for the quarter was 2 cents.
* The company reported quarterly net income of $1.88 million.
* Chromadex Corp shares had fallen by 1.9% this quarter and gained 150.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 50.1% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Chromadex Corp is 6.35 This summary was machine generated from LSEG data November 1 at 03:09 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.00 0.02 Beat
Jun. 30 2024 -0.02 0.00 Beat
Mar. 31 2024 -0.02 -0.01 Beat
Dec. 31 2023 -0.03 0.00 Beat
Comments